n-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide has been researched along with Autoimmune Experimental Myasthenia Gravis in 1 studies
N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide: structure given in first source
NS-398 : A C-nitro compound that is N-methylsulfonyl-4-nitroaniline bearing an additional cyclohexyloxy substituent at position 2.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Mu, L | 1 |
| Zhang, Y | 1 |
| Sun, B | 1 |
| Wang, J | 1 |
| Xie, X | 1 |
| Li, N | 1 |
| Zhang, J | 1 |
| Kong, Q | 1 |
| Liu, Y | 1 |
| Han, Z | 1 |
| Wang, G | 1 |
| Fu, Z | 1 |
| Yu, B | 1 |
| Li, G | 1 |
| Li, H | 1 |
1 other study available for n-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide and Autoimmune Experimental Myasthenia Gravis
| Article | Year |
|---|---|
Activation of the receptor for advanced glycation end products (RAGE) exacerbates experimental autoimmune myasthenia gravis symptoms.
Topics: Animals; Autoantibodies; Cell Proliferation; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cytokine | 2011 |